Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, reports the quality of life (QOL) in three trials; MONALEESA-2, 3, and 7. The MONALEESA-2 trial (NCT01958021) investigated the efficacy of the ribociclib (LEE01) in postmenopausal women with hormone receptor-positive (HR+), HER2 negative (HER2–) advanced breast cancer (ABC). The MONALEESA-3 trial (NCT02422615) investigated the use of ribociclib plus fulvestrant in postmenopausal women and men with HR+, HER2– ABC who have received no or one line of endocrine therapy. Finally, the MONALEESA-7 trial (NCT02278120) investigated the use of ribociclib in premenopausal women and HR+/HER2− ABC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).